Glenmark commences 1000 patients Post Marketing Surveillance study with COVID-19 who are administered FabiFlu®

Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, has announced that it has commenced a Post Marketing Surveillance (PMS) study on FabiFlu® to closely monitor the efficacy and safety... Read more »